• April 12, 2021  

    Sydney Researchers Identify/Advance Potential Revolutionary New Drug Treatment for Fatal Childhood Cancer Bookmark

    George Lundberg, MD

    A press release from the Children’s Cancer Institute outlines hopeful results from experiments performed in mice and 3-D computer models that investigated a new treatment for the rare childhood brain tumor diffuse intrinsic pontine glioma (DIPG). The treatment consists of a combination of the drugs difluoromethylornithine (DFMO) and AMXT 1501. This combo is already being tested in clinical trials in adults with cancer, and will soon be tested in children with DIPG.

    .

  • April 12, 2021  

    Chemo for Glioblastoma May Work Better in Morning Than Evening Bookmark

    George Lundberg, MD

    A press release from ScienceDaily outlines results from a small study of patients receiving a standard, FDA-approved treatment (temozolomide) for glioblastoma. The results suggest that some patients may survive a few months longer, all because of time of day for administering the drug.

    .

  • April 12, 2021  

    FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma Bookmark

    George Lundberg, MD

    The U.S. Food and Drug Administration (FDA) has approved a cell-based gene therapy known as lisocabtagene maraleucel (brand name Breyanzi) for relapsed or refractory large B-cell lymphoma.

    .

  • April 12, 2021  

    Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer Bookmark

    George Lundberg, MD

    The ASCO Post reports new results from a clinical trial in which the drug nivolumab (Opdivo) nearly doubled progression-free survival compared to a placebo drug for people with muscle-invasive bladder cancer.

    .

  • April 12, 2021  

    FDA Grants Full Approval to Sacituzumab Govitecan for Triple-Negative Breast Cancer Bookmark

    George Lundberg, MD

    Recurrent triple-negative breast cancer is particularly difficult to treat. As reported by Cancer Network, the U.S. Food and Drug Administration (FDA) has now approved the drug sacituzumab govitecan (Trodelvy) for treating people with this disease, depending on their stage and treatment history.

    .

  • April 12, 2021  

    Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer Bookmark

    George Lundberg, MD

    The ASCO Post reports on new results from a clinical trial testing a combination of the drugs lenvatinib and pembrolizumab in people with advanced or recurrent endometrial cancer. The results show that, compared to standard chemotherapy, this drug combo improves both overall and progression-free survival—according to both statistical and clinical analysis.

    .

  • March 16, 2021  

    Acute Myeloid Leukemia (AML)—An Overview Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic update with treatment options for all stages of acute myeloid leukemia is comprehensive and clear. (Free registration required, written with a physician audience in mind.)

    .

  • March 9, 2021  

    How an Expert Would Treat His Own Advanced Lung Cancer

    With: Jack West, MD

    A new cancer diagnosis is overwhelming. Patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks lung cancer expert Howard (Jack) West, MD, how he would handle his own diagnosis of advanced lung cancer. Dr. West is a Princeton- and Harvard-educated oncologist with additional training and experience in Boston and Seattle focusing on lung cancer.… Read more »

  • February 20, 2021  

    Treatment of Stage IV- Metastatic or Recurrent Colon Cancer Bookmark

    George Lundberg, MD

    This CancerConnect article summarizes the latest treatment options for stage IV colorectal cancer.

    .

  • February 19, 2021  

    Renal Cell Carcinoma—An Overview Bookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    There are now many precision oncology treatments for the most common type of kidney cancer, renal cell carcinoma, which represents about 3% of all potentially lethal cancers in America. This summary from Medscape details all the traditional treatment approaches, as well as newer considerations.

    .